Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)

Slides:

Advertisements

Similar presentations

Philip J. Barter, et al. Circulation 2011;124:

Advertisements

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Sripal Bangalore, MD,

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Cognitive Safety Task Force: 2014 update

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

An assessment by the Statin Liver Safety Task Force: 2014 update

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Todd J.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

A review of PCSK9 inhibition and its effects beyond LDL receptors

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies Christie.

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.

Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study Tim Christen, MSc, Stella.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Meredith Kilgore, PhD, Paul Muntner, PhD, J

P. W. Boonstra, MD, PhD, Y. J. Gu, MD, PhD, C. Akkerman, BSc, J

Eveline Oestreicher Stock, MD, Christine T

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: Implications for clinical utility William.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

An assessment by the Statin Intolerance Panel: 2014 update

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Xing Wu, MD, PhD, Zhexin Yu, MD, MS, Wen Su, MD, PhD, Daniel A

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Higher long-term adherence to statins in rural patients at high atherosclerotic risk Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

A Clinical Pharmacist Patient-Safety Initiative to Reduce Against-Label Prescribing of Statins with Cyclosporine Donald G. Lamprecht, PharmD, Anne M.

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk Benoit J. Arsenault, PhD, Francine Petrides, PhD, Fatiha Tabet, PhD, Weihang Bao, PhD, G. Kees Hovingh, MD, PhD, S. Matthijs Boekholdt, MD, PhD, Stéphane Ramin-Mangata, BSc, Olivier Meilhac, PhD, David DeMicco, PharmD, Kerry-Anne Rye, PhD, David D. Waters, MD, John J.P. Kastelein, MD, PhD, Philip Barter, MD, PhD, Gilles Lambert, PhD Journal of Clinical Lipidology Volume 12, Issue 1, Pages 130-136 (January 2018) DOI: 10.1016/j.jacl.2017.10.001 Copyright © 2017 National Lipid Association Terms and Conditions

Figure 1 Plasma PCSK9 levels at baseline in patients with or without type II diabetes in the entire study sample and in patients separated on the basis of atorvastatin dose. ∗Significantly different from atorvastatin 10 mg group in patients without type II diabetes. #Significantly different from atorvastatin 10 mg group in patients with type II diabetes. Journal of Clinical Lipidology 2018 12, 130-136DOI: (10.1016/j.jacl.2017.10.001) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 2 Plasma Lp(a) levels at baseline in patients with or without type II diabetes in the entire study sample and in patients separated on the basis of atorvastatin dose. ∗Significantly different from atorvastatin 10 mg group in patients without type II diabetes. #Significantly different from atorvastatin 10 mg group in patients with type II diabetes. Journal of Clinical Lipidology 2018 12, 130-136DOI: (10.1016/j.jacl.2017.10.001) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 3 Changes in plasma PCSK9 levels after 3 months on placebo or torcetrapib in patients with and without type II diabetes. ∗Significantly different from baseline. Journal of Clinical Lipidology 2018 12, 130-136DOI: (10.1016/j.jacl.2017.10.001) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 4 Changes in plasma Lp(a) levels after 3 months on placebo or torcetrapib in patients with and without type II diabetes. ∗Significantly different from baseline. Journal of Clinical Lipidology 2018 12, 130-136DOI: (10.1016/j.jacl.2017.10.001) Copyright © 2017 National Lipid Association Terms and Conditions